Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

Gee J, Bailey H, Kim K, Kolesar J, Havighurst T, Tutsch KD, See W, Cohen MB, Street N, Levan L, Jarrard D, Wilding G.

Prostate. 2013 Jun;73(9):970-8. doi: 10.1002/pros.22644. Epub 2013 Jan 17.

2.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.

Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA.

Cancer Chemother Pharmacol. 2008 Jun;62(1):149-57. Epub 2007 Sep 21.

PMID:
17885756
3.

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.

Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 May 1;11(9):3410-6.

4.

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.

Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G.

Clin Cancer Res. 2004 Nov 15;10(22):7450-6.

5.

Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.

Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1107-15.

PMID:
15234045
6.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
7.

Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.

Wilding G, King D, Tutsch K, Pomplun M, Feierabend C, Alberti D, Arzoomanian R.

Invest New Drugs. 2004 Apr;22(2):131-8.

PMID:
14739661
8.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Rezazadeh H, McGovern J, Robinson E, DeMets D, Wilding G.

Invest New Drugs. 2003 Aug;21(3):367-72.

PMID:
14578686
9.

Phase I trial of perillyl alcohol administered four times daily continuously.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2003 Nov;52(5):361-6. Epub 2003 Aug 2.

PMID:
12904896
10.

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.

Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G.

J Clin Oncol. 2003 Jan 15;21(2):223-31.

PMID:
12525513
11.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.

Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):465-72. Epub 2002 Oct 2.

PMID:
12451473
12.

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.

Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G.

Clin Cancer Res. 2002 Jul;8(7):2193-201.

13.

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.

Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G.

Clin Cancer Res. 2002 Mar;8(3):706-11.

14.

Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G.

Clin Cancer Res. 2002 Jan;8(1):86-94.

15.

Phase I clinical and pharmacokinetic trial of irofulven.

Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2001 Dec;48(6):467-72.

PMID:
11800027
16.

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.

Carbone PP, Pirsch JD, Thomas JP, Douglas JA, Verma AK, Larson PO, Snow S, Tutsch KD, Pauk D.

Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):657-61.

17.

Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Thomas J, Tutsch K, Pomplun M, Hamielec M, Pauk D.

Clin Cancer Res. 2000 Oct;6(10):3850-4.

18.
19.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

20.

Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.

Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G.

J Clin Oncol. 1999 Sep;17(9):2922-31.

PMID:
10561372
21.

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).

Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G.

Invest New Drugs. 1999;17(1):63-72.

PMID:
10555124
22.

Low-dose difluoromethylornithine and polyamine levels in human prostate tissue.

Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G.

J Natl Cancer Inst. 1999 Aug 18;91(16):1416-7. No abstract available.

PMID:
10451448
23.

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):989-92.

24.

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12.

25.

Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.

Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, Church D, Marnocha R, Cheng AL, Kehrli N, Wilding G.

Clin Cancer Res. 1998 Jun;4(6):1429-36.

26.

Phase I clinical trial of perillyl alcohol administered daily.

Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH.

Clin Cancer Res. 1998 May;4(5):1159-64.

27.

Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.

Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G.

J Clin Oncol. 1998 Mar;16(3):1142-9.

PMID:
9508201
28.

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G.

J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96.

PMID:
9392620
29.

Lack of thermal enhancement for taxanes in vitro.

Rietbroek RC, Katschinski DM, Reijers MH, Robins HI, Geerdink A, Tutsch K, d'Oleire F, Haveman J.

Int J Hyperthermia. 1997 Sep-Oct;13(5):525-33.

PMID:
9354937
30.

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.

Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G.

J Clin Oncol. 1997 Feb;15(2):781-9.

PMID:
9053505
31.

Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.

Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, Wilding G, Stewart JA.

J Clin Oncol. 1997 Jan;15(1):158-64.

PMID:
8996137
32.

Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.

McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ.

Clin Cancer Res. 1996 Aug;2(8):1299-305.

33.

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.

Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Moser AR, Dove WF.

Cancer Res. 1996 Feb 15;56(4):710-4.

34.

Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.

Chan KK, Hong PS, Tutsch K, Trump DL.

Cancer Res. 1994 Dec 15;54(24):6421-9.

35.

A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.

Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.

Semin Oncol. 1994 Oct;21(5 Suppl 8):9-14.

PMID:
7524159
36.

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.

J Clin Oncol. 1994 Feb;12(2):241-8.

PMID:
7509380
37.

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.

J Clin Oncol. 1994 Jan;12(1):194-205.

PMID:
8270977
38.

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G.

Invest New Drugs. 1994;12(2):137-41.

PMID:
7860231
39.

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.

Schiller JH, Storer B, Arzoomanian R, Tutsch K, Alberti D, Spriggs D.

Invest New Drugs. 1993 Nov;11(4):291-300.

PMID:
8157471
40.

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C, et al.

J Clin Oncol. 1993 Sep;11(9):1787-94.

PMID:
8355046
41.

Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.

Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G.

J Natl Cancer Inst. 1993 May 5;85(9):732-7.

PMID:
8478959
42.

Evidence of an absorption phase after short intravenous suramin infusions.

Hutson PR, Tutsch K, Spriggs D, Christian M, Rago R, Mutch R, Wilding G.

Cancer Chemother Pharmacol. 1993;31(6):495-9.

PMID:
8453691
43.

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR.

Cancer Chemother Pharmacol. 1992;30(4):297-302.

PMID:
1643698
44.

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD.

J Clin Oncol. 1991 Nov;9(11):2027-35.

PMID:
1941062
45.

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

Bailey H, Mulcahy RT, Tutsch KD, Rozental JM, Alberti D, Arzoomanian RZ, Tombes MB, Trump DL, Wilding G.

Cancer Res. 1991 Feb 15;51(4):1099-104.

46.

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G.

Cancer Res. 1991 Feb 15;51(4):1105-8.

47.

Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.

Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, Tombes MB, Bruggink J, Willson JK, Trump DL.

Cancer Res. 1990 May 1;50(9):2667-72.

48.

Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.

Remick SC, Benson AB 3rd, Weese JL, Willson JK, Ramirez G, Wirtanen GW, Alberti DB, Nieting LM, Tutsch KD, Fischer PH, et al.

Cancer Res. 1989 Nov 15;49(22):6437-42.

49.

Inadvertent administration of 480 mg/m2 of cisplatin.

Schiller JH, Rozental J, Tutsch KD, Trump DL.

Am J Med. 1989 May;86(5):624-5. No abstract available.

PMID:
2712074
50.

Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.

Willson JK, Fischer PH, Remick SC, Tutsch KD, Grem JL, Nieting L, Alberti D, Bruggink J, Trump DL.

Cancer Res. 1989 Apr 1;49(7):1866-70.

Supplemental Content

Loading ...
Support Center